We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Anivive Lifesciences announced the initiation of two pre-clinical studies to further evaluate the in vivo efficacy and safety of GC376 as a treatment for COVID-19.